Experimental Study Of Octreotide On Angiogenesis Of Hepatic W-256 Carcinoma By Transcatheter Arterial Infusion And Port Vein Infusion

Objectives: To evaluate the effect of octreotide on angiogenesis of hepatic W-256 carcinoma by transcatheter arterial infusion(TAI) and port vein infusion(PVI),and to investigate its possible mechanism and its clinical signification.Methods: Forty-nine SD rats with hepatic W-256 carcinoma were randomly divided into three groups two weeks after implantation,then treated with octreotide (experimental group),5-FU(positive control group) or normal saline(control group)by TAI and PVI respectively.After 7 days adding drug ,eight rats in each group were killed then the tumor inhibitory rate was assessed. The morphological changes of the tumor and hepatic tissue were also investigated under light microscope. Microvessel density(MVD), matrix metalloproteinase-2(MMP-2) and vascular endothelial growth factor (VEGF) expression were examined by immunohistochemistry. The rest rats in each group were used to assess survival time.Results: 1. The average tumor volume in the control group was 10.02 ±2.21 (cm3) but it was only 3.97±0.21 (cm3) in the experimental group. It was obviously inhibited in the experimental group as compared with the control group(P<0.05).The tumor growth inhibitory rate in experimental group was 62%. 2. The survival time of the rats in the experimental group was obviously longed as compared with the control group (P<0.05). 3. The MVD were detected by immunohistochemistory staining. It was 20.64 ± 0.44 in experimental group .It was downregulated as compared with the control group(P<0.05) in which the MVD was 30.63 ± 0.94. 4. In comparing with the control group, the expression of MMP-2 in experimental group was inhibited obviously. 5. Significantly decreased VEGF expression was also observed in experimental group as compared with control group by immunohistochemistory staining.Conclusions: 1. Octreotide used by TAI and PVI can inhibit the hepatic W-256 carcinoma. 2. The survival time of rats with hepatic W-256 carcinoma was prolonged by octreotide that was used by TAI and PVI. 3. By TAI and PVI, octreotide can inhibit angiogenesis of the hepatic W-256tumor. 4. The expression of VEGF in hepatic W-256 tumor tissue was inhibited by octreotide that was used by TAI and PVI. 5. Octreotide can inhibit the expression of MMP-2 in hepatic W-256 tumor tissue by TAI and PVI.